Catalog No.
DHD37501
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20138
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CDP-771, CMA-676 (ADC), WAY-CMA-676, gemtuzumab ozogamicin, CAS: 220578-59-6
Clone ID
Gemtuzumab
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials, PMID: 25008258
Gemtuzumab ozogamicin in acute myeloid leukemia, PMID: 28607471
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia, PMID: 29787320
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial, PMID: 30076173
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future, PMID: 32955828
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment, PMID: 32781546
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia, PMID: 33059764
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers, PMID: 31462392
Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab, PMID: 28003274
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group, PMID: 30093401
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study, PMID: 31851556
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study, PMID: 22482940
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia, PMID: 31880804
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial, PMID: 33367545
Gemtuzumab ozogamicin, PMID: 11511025
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial, PMID: 26811524
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531, PMID: 25092781
Acute myeloid leukaemia, PMID: 30078459
Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin, PMID: 32988266
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia, PMID: 23591789
Acute myeloid leukemia: 2021 update on risk-stratification and management, PMID: 32833263
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial, PMID: 21172891
Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come, PMID: 30598494
[Intraperitoneal perfusion of gemtuzumab-ozogamicin combined with allogeneic hematopoietic stem cell transplantation in intestinal solitary myeloid sarcoma: a case report and literature review], PMID: 32942825
Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia, PMID: 26646091
[Gemtuzumab ozogamicin for treatment of acute myeloid leukemia], PMID: 24557850
Gemtuzumab ozogamicin in acute myeloid leukemia revisited, PMID: 24865510
How I diagnose and treat NPM1-mutated AML, PMID: 33171486
Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia, PMID: 12503209
Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia, PMID: 21810061
[Gemtuzumab ozogamicin and targeted cancer therapy], PMID: 15226619
Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia, PMID: 16266206
Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome, PMID: 30797942
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia, PMID: 18352855
Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin, PMID: 16562371
Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience, PMID: 33219461
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia, PMID: 17942233
AML: New Drugs but New Challenges, PMID: 32151586
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia, PMID: 12162910
[Gemtuzumab ozogamicin as monotherapy and combination therapy for acute myelogenous leukemia], PMID: 17633093
Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis, PMID: 24033280
New drugs creating new challenges in acute myeloid leukemia, PMID: 30861214
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia, PMID: 14601078
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy, PMID: 21142804
Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials, PMID: 18063879
The optimal dosing of gemtuzumab ozagamicin: where to go from here?, PMID: 27252508
[Gemtuzumab ozogamicin combined chemotherapy for elderly patients with acute myeloid leukemia], PMID: 24881915
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia, PMID: 30039981
Gemtuzumab Ozogamicin Makes a Comeback, PMID: 28931515
Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report, PMID: 32871966
For research use only. Not for human or drug use.
